GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2-4: a target trial emulation

Published in Diabetol Metab Syndr. Imported from PubMed. This was filed by the system importer, not a fake user. Possible receipts (auto-attached from public APIs — verify before trusting): - PubMed: Distinct temporal neuropsychiatric outcomes associated with GLP-1 receptor agonists versus SGLT2 inhibitors after acute kidney disease in type 2 diabetes — https://pubmed.ncbi.nlm.nih.gov/43010906/ - PubMed: GLP-1 receptor agonists for people with type 2 diabetes and peripheral artery disease: reducing uncertainty in clinical practice — https://pubmed.ncbi.nlm.nih.gov/43007383/ - ClinicalTrials.gov: iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases — https://clinicaltrials.gov/study/NCT03549754